BACKGROUND: Intrathecal neostigmine not only produces analgesia but also severe nausea. In contrast, epidural neostigmine enhances opioid and local anesthetic analgesia without causing nausea. Previous studies examined only single epidural neostigmine bolus administration and did not assess the efficacy of continuous epidural infusion or several aspects of maternal and fetal safety. We therefore tested the hypothesis that epidural neostigmine in combination with bupivacaine by continuous infusion during labor would reduce the amount of bupivacaine required. METHODS: Twelve healthy women scheduled for elective cesarean delivery were assigned to receive epidural neostigmine, 40 g (first six subjects) or 80 g (second six subjects) as a single bolus, with fetal heart rate (FHR) and uterine contractions monitored for 20 min. In a subsequent experiment, 40 healthy laboring women were randomized to receive bupivacaine 1.25 mg/mL alone or with neostigmine 4 g/mL by patient-controlled epidural analgesia. The primary outcome measure was hourly bupivacaine use. RESULTS: Epidural neostigmine bolus did not alter baseline FHR, induce contractions, or produce nausea. Epidural neostigmine infusion reduced bupivacaine requirement by 19% in all patients and 25% in those with Ͼ4 h of treatment (P Ͻ 0.05 for both) but might have contributed to the incidence of mild sedation. Mode of delivery, incidence of maternal nausea, and FHR abnormality were similar between groups. CONCLUSIONS: These data show that adding epidural neostigmine 4 g/mL reduces the hourly bupivacaine requirement by 19%-25% with patient-controlled epidural analgesia during labor. Administered as a bolus and by continuous infusion at the studied doses, epidural neostigmine does not cause nausea and does not induce uterine contractions or FHR abnormalities, but mild sedation can occur.
epidural labor analgesia, their use can be complicated by maternal hypotension and motor block, especially with prolonged infusions. Dense motor block is unwanted and uncomfortable in this setting, and may increase the risk of instrumental delivery, as suggested by controlled studies and meta-analysis. 1 For this reason, adjuvant opioids are added to decrease local anesthetic use and to minimize motor block. 2 Neuraxial opioids, however, produce pruritus, increase the incidence of respiratory depression, and decrease fetal heart rate (FHR) variability. 3 Additionally, extra time may be required to document use of a controlled substance.
Other drugs have been introduced as adjuvants to local anesthetics for neuraxial analgesia. Intrathecal injection of the cholinesterase inhibitor neostigmine increases extracellular acetylcholine concentrations within the spinal cord, leading to increased stimulation of spinal muscarinic and possibly nicotinic receptors to produce analgesia. 4 After animal toxicity studies 5 and Phase I safety studies, 6, 7 intrathecal neostigmine entered clinical trials, including laboring parturients, in which it demonstrated not only efficacy but also severe nausea and vomiting. 8 -10 In contrast, more recent studies of single epidural bolus administration of neostigmine have shown it to produce effective analgesia without severe nausea and vomiting. [11] [12] [13] Few studies have examined the safety and efficacy of epidural neostigmine in obstetrics, and these are limited to single bolus studies, which demonstrated an analgesic effect associated with mild sedation without severe nausea or vomiting. 14 -16 Fetal bradycardia and enhanced uterine contractions have been noted with systemic or IVadministered neostigmine. 17, 18 Significant effects of neostigmine on FHR or uterine contractions could be overlooked during active labor. We therefore performed a two-phase study. The purpose of the first phase was to assess safety by examining the effects of epidural neostigmine on uterine activity and FHR in term pregnant nonlaboring women. For this study, we used a classic open label, dose escalating safety study design. The goal and power of this first phase was to observe for common (10%-20% or more) and significant side effects, if any, and to help determine a safe neostigmine dose for initiation and continuous infusion of labor epidural analgesia.
In Phase II of our study, we tested the hypothesis that continuous epidural neostigmine infusion would significantly reduce bupivacaine requirement in women during maintenance patient-controlled epidural analgesia (PCEA) for labor.
METHODS

Regulatory Issues
Neostigmine intrathecal toxicity studies supporting bolus intrathecal administration have been reported previously, 4, 5 and the authors hold an Investigational New Drug approval from the United States Food and Drug Administration for clinical investigation of intrathecal neostigmine. Because fibrosis of epidural catheters develop rapidly in rats, 19 we were unable to repeat toxicity testing by this route in the rat model. We are unaware of any drugs which are safe when administered intrathecally but neurotoxic when administered epidurally, even though the converse may occur. 20 An independent Data Safety Monitoring Board reviewed the results, including an obstetrician's review of the FHR uterine contraction tracings, at the conclusion of each group of 10 subjects using standard criteria. 21, 22 This study consisted of two phases: (I) pilot safety assessment of epidural neostigmine before elective cesarean delivery in nonlaboring patients and (II) double-blind, randomized, controlled trial of continuous epidural neostigmine with bupivacaine compared with bupivacaine alone for labor analgesia. Neostigmine methylsulfate with preservatives (1 mg/mL, American Regent, Shirley, NY) and preservative-free bupivacaine (2.5 mg/mL, Hospira, Lake Forest, IL), together with normal saline, were used to make the epidural study solutions. Intrathecal safety assessment for neostigmine methylsulfate with preservatives had been previously reported by the authors. 6, 7 The institutional review board, Wake Forest University School of Medicine, Winston-Salem, NC, approved both phases of the study.
I. Pilot Safety Assessment Before Elective Cesarean Delivery
Written informed consent for study participation was obtained from 12 healthy adult parturients scheduled for elective cesarean delivery. Peripheral IV access was established and all patients received a 15 mL/kg bolus of lactated Ringer's solution. A multiport epidural catheter was inserted at the L3-4 or L4 -5 interspace. A 3-mL epidural test dose of lidocaine 20 mg/mL plus epinephrine 5 g/mL was injected and, 5 min later, the first six patients received epidural neostigmine 40 g in a 2-mL solution, whereas the next six patients received 80 g. These doses were chosen to encompass the bolus dose and the likely hourly exposure patients would receive in the second phase of the study.
Continuous FHR, uterine contractions (with external tocodynometry), maternal vital signs, and Spo 2 were recorded before epidural catheter insertion and every 5 min for 20 min thereafter. Women were also asked to rate pain, nausea, pruritus, and sedation using a verbal rating scale every 5 min for 20 min, and immediately before transfer to the operating room and in the postanesthesia care unit. The verbal rating scale ranged from 0 to 10 by self-assessment with 0 being no pain, nausea, pruritus, or sedation, respectively, and 10 being the worst pain imaginable, worst nausea, worst pruritus, or asleep.
At the end of this 20-min observation period, women received 2-chloroprocaine 30 mg/mL by incremental epidural injection to establish anesthesia. Maternal vital signs were recorded every 5 min or more frequently, if needed, during initiation of epidural anesthesia and surgery. Medication administered and obstetrical, surgical, and neonatal outcomes were recorded. FHR, external tocodynometry, and Spo 2 were continuously monitored until transfer of the patients to the operating room. Patients were queried regarding onset or presence of uterine contractions every 5-10 min, and maternal vital signs were recorded every 5 min. FHR and uterine contraction tracings were evaluated at a later time by an obstetrician blinded to type of drug treatment. Supplemental intraoperative anesthesia consisted of additional epidural 2-chloroprocaine and fentanyl and IV morphine as needed. Once in the postanesthesia care unit dermatomal level of sensory analgesia was evaluated at 15-min intervals until sensory blockade to pinprick receded to the T10 dermatome.
labor and cervical dilation Յ6 cm. Epidural analgesia was initiated at patient request and with a minimum verbal pain score of 4 or more. A lumbar epidural catheter was inserted and a combined IV and intrathecal test dose consisting of lidocaine 45 mg and epinephrine 15 g was administered. A computer-generated random number table was used to provide randomization of patient allocation, which was concealed in sealed envelopes. At the time of patient's request for epidural analgesia administration, an attending anesthesiologist (who was familiar with the study protocol but not involved with the care of the patient or data collection) then opened the sealed envelope for group assignment and prepared the study solution. The patients, the investigators, and the research personnel involved in the data collection, as well as the personnel involved in the medical care of the patients, were all blinded to the assignment and study drug. Patients were randomized to receive 15 mL (in 5 mL increments) of bupivacaine 1.25 mg/mL or bupivacaine 1.25 mg/mL with neostigmine, 0.004 mg/mL. If the patient failed to achieve analgesia (failed analgesia was defined as verbal pain score Ͼ3) 20 min after this injection, they were excluded from the study and the epidural catheter replaced.
After successful analgesia (verbal pain score Յ3) was achieved, maintenance epidural analgesia was initiated with the assigned solution via PCEA (basal infusion rate, 6 mL/h; PCEA bolus, 5 mL; lockout interval, 10 min; maximum dose, 30 mL/h). Breakthrough pain in the first stage of labor was treated with an anesthesiologist-administered bolus of 5-10 mL bupivacaine 2.5 mg/mL to comfort (verbal pain score Յ3) and 2-chloroprocaine 20 mg/mL or lidocaine 20 mg/mL, 5-10 mL (in 5 mL increments) in the second stage of labor. Patients were excluded from the study if they required more than one anesthesiologistadministered dose per 2 h or were not comfortable (verbal pain score Ͼ3) after receiving 10 mL bupivacaine 2.5 mg/mL during the first stage of labor.
Pain was assessed before epidural catheter insertion, at 5 min after test dose, every 5 min for the first 20 min after the initial study drug administration, then every 2 h until delivery. Maternal vital signs were recorded at the same times as pain assessments or more frequently, if indicated. Dermatomal level of sensory block to pinprick testing, degree of motor block (using a 0 -3 scale 23 ), maternal sedation, and nausea (using a 0 -10 verbal rating scale selfassessment) were assessed at the same times as pain assessments. The patients were instructed to rate their sedation based on their subjective feeling of sedation/sleepiness using a verbal rating score with 0 being wide awake and not feeling sleepy at all to 10 being asleep. Nausea was rated with 0 being no nausea to 10 being worst nausea imagined. Maternal hypotension was defined as a decrease of 20% from systolic blood pressure obtained at admission. The presence of shivering (by patient self-assessment), maternal hypotension and abnormalities of FHR pattern, 21, 22 mode of delivery, infant weight, 1 and 5 min Apgar scores, total volume of study solution, PCEA bolus demands and anesthesiologist-administered bolus doses, and any medication administered were recorded. FHR and uterine contraction tracings for the duration of labor after initiation of epidural analgesia were evaluated by an obstetrician 21, 22 blinded to patient group assignment. After delivery before patients returned to the postpartum ward, the patients were asked to rate the overall degree of satisfaction of epidural analgesia for the duration of labor using a 1-3 verbal scale (1 ϭ unsatisfactory analgesia, 2 ϭ satisfactory analgesia, and 3 ϭ excellent analgesia).
Data Analysis
Data are presented as mean Ϯ sd or incidence (%). Based on our obstetric unit quality assurance data and previous observations, 2 we estimated the total hourly consumption of bupivacaine (including anesthesiologistadministered boluses) during labor to be the equivalent of 14 mL of bupivacaine 1.25 mg/mL with a standard deviation of 3.0 mL. For the labor study, a prior sample size analysis with the above assumption and with a ␤ of 0.20 and ␣ of 0.05 demonstrated that a sample size of 20 per group would allow us to detect a 20% difference in total epidural drug required per hour. Before study initiation, we planned a separate analysis of drug use among those with labor analgesia Ͼ4 h. The primary outcome variable analyzed in the labor study was hourly bupivacaine use, using a two-tailed t-test. Incidence and proportion data were compared between groups using 2 or Fisher's exact test. Sedation, shivering, pruritus, nausea, and motor block were considered present if the score was more than zero. Nonparametric data were analyzed with Mann-Whitney U-test. Change in continuous measures over time within each dose group was determined using one-way analysis of variance for repeated measures and two-way analysis of variance for comparison between groups. P Ͻ 0.05 was considered significant.
RESULTS
I. Pilot Safety Assessment Before Cesarean Delivery
Study participants were 30 Ϯ 7 yr old, 164 Ϯ 8 cm tall, and 82 Ϯ 19 kg in weight. The median gravidity and parity were 2 and 1, respectively, and median gestational age was 39 wk. Neostigmine was injected 5-10 min after the epidural test dose in all but one case, in which there was a 58-min interval because of an obstetric delay. At the time of neostigmine injection, a sensory level to pinprick was present in 8 of 12 women from the epidural test dose, with a median dermatomal level of T11 bilaterally. Fifteen minute after neostigmine injection, 9 of 12 women exhibited hypesthesia to pinprick testing, with a median dermatomal level of T10 on the left and T8 on the right. Two women had intermittent uterine contractions before neostigmine injection and had no interval change in frequency of contractions over the next 15 min after neostigmine injection. The obstetrician evaluating the FHR and uterine contraction tracings did not consider the uterine contractions in these two women to have temporal relationship or cause-effect relationship with the neostigmine injection. The mean FHR was 137 Ϯ 18 bpm at the time of neostigmine injection and 139 Ϯ 18 bpm 15 min later. There were no episodes of fetal bradycardia or alterations in long-term beat-to-beat variability as assessed by external monitoring. Maternal arterial blood pressure, heart rate, and level of pain, pruritus, and sedation were not altered after epidural neostigmine (data not shown). One patient in each dose group experienced nausea after neostigmine injection, but in each case it was rated 1 on the 0 -10 scale. The mean interval from neostigmine injection to local anesthetic injection was 22 min (excluding one case in which the neostigmine injection to local anesthetic injection was 98 min because of an obstetrical delay). Uterine incision occurred 68 Ϯ 31 min after neostigmine injection. Maternal arterial blood pressure and heart rate did not differ between neostigmine dose groups, and four of six women in each group received ephedrine for hypotension after epidural administration of local anesthetic. All neonates had a 1-min Apgar score Ͼ7 and a 5-min Apgar score Ͼ8.
II. Randomized Controlled Trial in Labor
Fifty women were recruited, with 10 excluded from study because of no block and inadequate analgesia from the initial epidural dose (three in bupivacaine ϩ neostigmine group), epidural catheter dislodgement (one in bupivacaine ϩ neostigmine group), failure of the epidural analgesia requiring Ն2/2 h anesthesiologist administered boluses during labor (one in each group), recognition of breech presentation after epidural catheter was inserted (one in bupivacaine alone group), protocol violation because of IV butorphanol administration within 30 min before epidural catheter placement (two excluded before randomization for group assignment), or informed consent obtained but the study never initiated (one excluded before randomization for group assignment). The bupivacaine alone (n ϭ 20) and bupivacaine ϩ neostigmine (n ϭ 20) groups of the remaining 40 women who completed the study did not differ in demographic or labor characteristics ( Table 1) .
Safety and Outcome of Labor
Maternal arterial blood pressure was similar in the two groups before initiation of analgesia and was reduced to a similar degree during initiation of epidural analgesia (Fig. 1A) . Five patients in the bupivacaine alone group and seven in the bupivacaine ϩ neostigmine group received treatment for hypotension (P ϭ NS). Maternal heart rate between contractions before and after epidural analgesia was similar between groups and was not affected by epidural analgesia (data not shown). FHR was similar between groups before and after epidural analgesia (Fig. 1B) , and there was one case in each group of variable FHR decelerations within the 20 min of initial epidural dose administration. One patient in each group underwent cesarean delivery for nonreassuring FHR. The obstetrician (blinded to group/drug assignment) evaluating the FHR and uterine contraction tracings in the context of the patient's obstetric history and clinical presentation did not find any of these changes to be temporally or directly associated with the study or control drug administration. Groups did not differ in Apgar scores and there were no 1-min scores of Ͻ7 or 5-min scores of Ͻ8 in either group. Progress of labor was unaffected by the addition of neostigmine. Cervical dilation was similar between groups at the time of initiation of analgesia and 2 h later (Table 1) .
Additionally, for all those who reached complete cervical dilation, the time until complete cervical dilation did not differ between bupivacaine alone (5.1 Ϯ 3.8 h) and bupivacaine ϩ neostigmine (4.6 Ϯ 2.2 h). The mode of delivery did not differ between groups, with four cesarean deliveries in each, and one forceps and one vacuum extraction in the bupivacaine ϩ neostigmine group.
The sedation score was increased compared with baseline from 5 to 20 min after initiation of analgesia in the bupivacaine ϩ neostigmine group (P Ͻ 0.05) but not in the bupivacaine-alone group. The incidence of sedation also increased over the first 20 min in the bupivacaine ϩ neostigmine group but not in the bupivacaine alone group ( Fig. 2A) ; P Ͻ 0.05. There was no significant difference in sedation scores between groups at any time. The incidence of sedation in the bupivacaine ϩ neostigmine group was not increased after the initial dosing period ( Fig. 2A) . The intensity of sedation among those reporting a nonzero score did not differ at any time between the groups. However, the median maximum sedation scores were 0 (range 0 -10) for bupivacaine alone group and three (range 0 -6) for bupivacaine ϩ neostigmine group, whereas the mode was 0 for both groups. Groups also did not differ in incidence or severity of motor block at any time during the study period. The median and mode of the nonzero motor blockade score were 1 for both groups. The mode and median maximum motor blockade scores from each patient were both 1 (range 0 -2) for both groups. Groups did not differ in the incidence of pruritus or shivering at any time, and the incidence of these effects did not increase after initiation of analgesia (data not shown). The incidence of nausea was not different between groups (Fig. 2B) . One patient in the bupivacaine alone group, received treatment for nausea.
Efficacy
Pain scores rapidly decreased (Table 1) after initiation of analgesia and did not differ between groups at any time during the study. The median number of patient demands with PCEA was greater in the bupivacaine alone group than in the bupivacaine ϩ neostigmine group (13 vs 4, respectively; P Ͻ 0.05). The groups did not differ, however, in the number of patients requiring physician-administered top-up doses (9 vs 7, respectively) or the number of top-up doses among those who received at least one physician-administered dose (median value 1, range 1 and 3, and interquartile range 1 and 2, for both groups). The mean bupivacaine dose was 14.7 Ϯ 4.7 mL/h in the bupivacaine group versus 11.9 Ϯ 3.0 mL/h in the bupivacaine ϩ neostigmine group (P Ͻ 0.05) in all patients, and 15.6 Ϯ 3.3 mL/h vs 11.7 Ϯ 2.7 mL/h, respectively, in patients with prolonged (Ͼ4 h) analgesia (P Ͻ 0.05). Twenty-five patients (12 in bupivacaine group and 13 in bupivacaine ϩ neostigmine group) received prolonged analgesia. The addition of neostigmine reduced the mean hourly epidural dose of bupivacaine by 19% in the entire population and by 25% in those receiving study solution for more than 4 h (both P Ͻ 0.05; Fig. 3 ). Groups did not differ in satisfaction with analgesia (data not shown).
DISCUSSION
This study demonstrates an absence of a significant direct effect on FHR and uterine contractions from epidural neostigmine (up to 80 g bolus) at term gestation in the absence of labor or analgesia. This study also demonstrates a bupivacaine-sparing effect with continuous administration of low-concentration (4 g/mL) epidural neostigmine similar to that observed with fentanyl 2 without the presence of nausea, pruritus, or apparent adverse FHR or neonatal effect. Interestingly, we confirmed previous observations 14 of neostigmine-induced sedation after a neostigmine bolus, but this side effect was mild and not sustained with continued treatment.
Intrathecal neostigmine in large doses for prolonged periods failed to cause neurotoxicity in animals, 4, 5 and clinical trials of intrathecal and epidural neostigmine have raised no concerns regarding neurotoxicity. Intrathecal neostigmine has been associated with severe nausea and vomiting. 6 -10 This side effect is absent when neostigmine is administered by the epidural route, although the reasons for this difference are obscure. [11] [12] [13] Nonetheless, the current study supports previous observations that epidural neostigmine does not increase the incidence of nausea after a bolus during labor 15, 16 or after surgery 11, 13, 14 and now extends this finding to the nonlaboring women at term gestation (without the confounding effects of labor, analgesia and anesthesia) and to laboring women who receive neostigmine via patient-controlled continuous epidural infusion for labor analgesia. Intrathecal 9,10 and epidural 14 bolus administration of neostigmine increases sedation scores, although no more than a moderate degree of sedation has been noted. Transient sedation with initiation of epidural or spinal analgesia in labor has been frequently observed, and may reflect maternal relaxation from the prolonged stress of sustained pain during labor or, in the case of opioids, from the drug itself. We observed an increase in incidence of sedation in the 20 min after initiation of labor analgesia when neostigmine was added to bupivacaine compared with bupivacaine alone, although the degree was mild (median maximum sedation score from each patient was 0 for bupivacaine alone group and three for bupivacaine ϩ neostigmine group). Because degrees of pain relief did not differ between groups, we conclude that this sedation was at least in part because of neostigmine. Groups did not differ in Apgar scores and there were no 1-min scores of Ͻ7 or 5-min scores of Ͻ8 in either group. Although sedation was mild and shorter than 2 h in duration, without any apparent detrimental maternal or neonatal effects, future studies are needed to determine more precisely whether the incidence, duration, and severity of this side effect would increase with doses and duration above what we studied. Before the study, we had anticipated the sedative effect of low-dose epidural neostigmine to be very minimal if any. Therefore, we chose to use a selfassessed verbal rating score especially for measuring the low level of sedative effect as perceived by the patients. This form of self-assessed verbal rating sedation score has been used and validated with high correlation with Observer's Assessment of Alertness/Sedation score and Bispectral Index, especially for measuring the mild degree of sedation from epidural or spinal anesthesia. 24, 25 In the bupivacaine ϩ neostigmine group, the highest maximum sedation score obtained for anyone was 6, whereas the median maximum sedation score was only 3. However, such self-assessed sedation verbal rating score has its limitation at the high end of the score (such as 9 or 10), in which the patient is asleep or too sleepy to accurately differentiate the different level of much deeper sedation. If much deeper sedation level (such as in difficult to arouse patients) is anticipated, observer's assessment, such as Observer's Assessment of Alertness/Sedation, may be more appropriate than self-assessment.
Stimulation of spinal cholinergic receptors can increase sympathetic nervous system activity, 18 which may lead to decreased uteroplacental perfusion. We found no evidence for this effect with neostigmine at the doses we studied; there were no differences from the control group in maternal arterial blood pressure or heart rate or differences in the incidence of FHR abnormalities. The lack of effect of neostigmine on blood pressure may be related to dose of neostigmine or relative contributions of neostigmine and bupivacaine at the doses and concentrations studied. Additionally, systemic absorption of neostigmine could result in stimulation of myometrial activity 18 or, if transferred in adequate amounts to the fetus, 17 in fetal bradycardia. We found no evidence of either effect in either patients about to undergo elective cesarean delivery or in patients in labor. We were, however, limited to detecting only major changes in uterine contraction frequency and could not detect changes in intensity because nearly all our study patients had external monitors. These observations are reassuring and fail to raise concerns regarding the safety of epidural neostigmine in obstetrics. Nonetheless, this study, as are previous ones in this setting, 14 -16 was inadequately powered to exclude uncommon side effects, and we believe that epidural neostigmine should remain an investigational therapy at this time. This is the first study to examine continuous infusion of epidural neostigmine for labor analgesia. Others have demonstrated a much higher bolus dose of neostigmine (4 g/kg), when added to ropivacaine 10 mg, provided equivalent efficacy to ropivacaine 20 mg alone. 15 Roelants and Lavand'homme 16 also demonstrated that epidural neostigmine administered by bolus in combination with sufentanil was effective in reducing the dose of sufentanil needed to initiate labor analgesia, but they did not investigate the use of neostigmine by continuous infusion for maintenance of labor analgesia. We designed the labor phase of the study to investigate whether a low-neostigmine dose (with minimal or no side effects) would reduce the dose of epidural bupivacaine if used as an adjuvant for both the initiation and maintenance (as an infusion) of labor analgesia. Without previous data on epidural neostigmine infusion for labor analgesia, we conservatively chose the neostigmine infusion dose and bolus dose to give a cumulative dose within the upper limit of safe administration based on reports of bolus administration, and the result of our Phase I safety study. We used PCEA to allow women to titrate epidural study solutions. This method has been used in other studies to assess the local anesthetic-sparing properties of other additives. 2, 26, 27 As expected, the degree of pain relief was similar between groups in the current study, reflecting effective patient titration. However, the number of demands for the bupivacainealone group was significantly greater than when neostigmine was added, and the mean hourly bupivacaine dose requirement during labor was less in the neostigmine group. There were no differences at any time in motor block between groups in our study. The current study was not designed or powered to determine whether the reduction in bupivacaine dose resulted in less motor block, but results with fentanyl 1 would predict this to be the case. Additionally, we did not examine the dose-response for epidural neostigmine for continuous labor analgesia, but such dose-response studies in comparison with epidural bupivacaine with fentanyl (as control) or other adjuvants are needed.
In conclusion, epidural neostigmine, up to 80 g, does not alter maternal arterial blood pressure, FHR, or produce uterine contractions in nonlaboring term, healthy pregnant women. The addition of neostigmine, 4 g/mL, reduces up to 25% of epidural bupivacaine requirement with PCEA during labor. Except for mild sedation during initiation of labor analgesia, no significant adverse effect on progress of labor or on the mother and the fetus was observed with neostigmine doses studied. Epidural neostigmine should be considered an experimental, but possibly promising, alternative to opioids as an adjunct to labor epidural analgesia.
